Euronext Paris

Strong FY 2023 results, Planisware consistently delivering sustainable profitable growth

Retrieved on: 
Monday, March 11, 2024

At € 6.9 million, 2023 income tax expense reflected an Effective Tax Rate of 14.1%, compared to 15.5% in 2022.

Key Points: 
  • At € 6.9 million, 2023 income tax expense reflected an Effective Tax Rate of 14.1%, compared to 15.5% in 2022.
  • In 2023, adjusted Free Cash Flow reached
    € 43.8 million, up by +64.4% compared to € 26.7 million in 2022, led by Adjusted EBITDA growth.
  • Planisware benefits from a strong cash position, as most of its customers prepay for services, which generates structurally negative working capital requirements.
  • In 2023, Planisware initiated the next phase of its growth strategy through its contemplated IPO on Euronext Paris.

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

Retrieved on: 
Thursday, March 7, 2024

Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.

Key Points: 
  • Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
  • Other sites and countries are expected to resume screening and randomization activities progressively over the next weeks.
  • Clinical sites located in the United States operating under central IRB have meanwhile resumed screening and randomization activities.
  • Inventiva anticipates the last patient first visit for the NATiV3 clinical trial in the first half of 2024.

Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024

Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR).

Key Points: 
  • Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR).
  • The AACR will take place in San Diego, California, USA, from April 5 to 10, 2024.
  • The abstract will be available on the AACR website April 5, 2024, at 3:00 p.m.
  • Transgene and NEC plan to continue the development of TG4050 in this indication with a Phase II extension of the trial expected to start in 2024.

Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

Retrieved on: 
Tuesday, March 5, 2024

BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.

Key Points: 
  • BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.
  • The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture.
  • “Our collaboration with BostonGene has provided in-depth information on patient phenotypes in the Phase I trial.
  • “We are committed to supporting Transgene and NEC as they advance these clinical trials,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Retrieved on: 
Monday, March 4, 2024

Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.

Key Points: 
  • Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.
  • CEO Thomas Lingelbach will present Valneva at the TD Cowen 44th Annual Health Care Conference, taking place March 4 - 6, 2024, in Boston, MA.
  • Mr. Lingelbach and CFO Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen Life Sciences Conference, held April 16 - 17, 2024, in Amsterdam, The Netherlands.
  • VLA15, the Company’s Lyme disease vaccine candidate, is currently in Phase 3 clinical development and partnered with Pfizer for this study and global commercialization.

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

Retrieved on: 
Thursday, February 29, 2024

ACIP recommends IXCHIQ® for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.

Key Points: 
  • ACIP recommends IXCHIQ® for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.
  • ACIP also recommended chikungunya vaccination for laboratory workers with potential for exposure to CHIKV.
  • IXCHIQ offers advantages to travelers on vacation and visiting family and to people engaged in business ventures, missions, or laboratory duties.
  • We embrace the ACIP endorsement, marking IXCHIQ® as the only approved and recommended vaccine for the target population.

Stellantis Announces Launch of First Tranche

Retrieved on: 
Wednesday, February 28, 2024

AMSTERDAM, February 28, 2024 - Stellantis N.V. (“Stellantis” or the “Company”) announced today that pursuant to its Share Buyback Program (or the “Program”) announced on February 15, 2024, covering up to €3 billion (total purchase price excluding ancillary costs) to be executed in the open market, Stellantis has signed a share buyback agreement for the first tranche of its Program with an investment firm that will make its trading decisions concerning the timing of purchases independently of Stellantis.

Key Points: 
  • AMSTERDAM, February 28, 2024 - Stellantis N.V. (“Stellantis” or the “Company”) announced today that pursuant to its Share Buyback Program (or the “Program”) announced on February 15, 2024, covering up to €3 billion (total purchase price excluding ancillary costs) to be executed in the open market, Stellantis has signed a share buyback agreement for the first tranche of its Program with an investment firm that will make its trading decisions concerning the timing of purchases independently of Stellantis.
  • This agreement will cover a maximum amount of up to €1 billion (of the €3 billion Share Buyback Program).
  • The first tranche of the Program shall start on February 28, 2024 and end no later than June 5, 2024.
  • This is intended to support the benefits of expanding and strengthening the ownership culture of our teams, while avoiding dilution of existing shareholders.

Vantiva Demonstrates One of the First Carrier-Grade Wi-Fi 7 Extenders and Advanced 5G FWA CPE at Mobile World Congress 2024

Retrieved on: 
Monday, February 26, 2024

Barcelona – February 26, 2024 – Vantiva (Euronext Paris: VANTI), a global technology leader enabling Network Service Providers to connect consumers worldwide, today announced plans for Mobile World Congress (MWC) 2024.

Key Points: 
  • Barcelona – February 26, 2024 – Vantiva (Euronext Paris: VANTI), a global technology leader enabling Network Service Providers to connect consumers worldwide, today announced plans for Mobile World Congress (MWC) 2024.
  • With our 5G FWA gateways, Wi-Fi 7 extenders, and the NaviGate™ apps, we demonstrate how we've simplified installation and improved Wi-Fi coverage.”
    Cobra 5G and Falcon 5G FWA gateways use Vantiva’s breakthrough Indoor5G™ technology.
  • With its WanSensing™ feature, the Cobra 5G gateway can switch between wired and 5G connectivity to always support reliable service continuity.
  • Vantiva’s 5G FWA product range comes equipped with the NaviGate 5G™ app, allowing end-users self-installation, hence reducing operators’ OPEX.

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

Retrieved on: 
Tuesday, February 20, 2024

The Company listed the ADSs on The Nasdaq Global Select Market in November 2017 under the ticker ERYP, and subsequently transferred the listing of its ADSs to The Nasdaq Capital Market in April 2023.

Key Points: 
  • The Company listed the ADSs on The Nasdaq Global Select Market in November 2017 under the ticker ERYP, and subsequently transferred the listing of its ADSs to The Nasdaq Capital Market in April 2023.
  • “Given PHAXIAM’s current stage of development, we have determined that delisting from the Nasdaq market was the wisest business and financial decision for the company.
  • PHAXIAM Therapeutics remains listed on Euronext Paris as its primary trading market and intends to continue its disclosures in compliance with applicable French financial market regulations.
  • Investors will receive either the underlying ordinary shares (if those have not yet been sold by the Depositary) or the cash received by the Depositary received upon sale of underlying ordinary shares, net of fees, if those underlying ordinary shares were sold.

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

Retrieved on: 
Wednesday, March 6, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).
  • The study is planned to enroll up to 184 patients.
  • “We are pleased to announce the dosing of a first patient in this Phase 1/2 study evaluating IPH6501, our proprietary ANKET® asset and the first tetraspecific NK Cell Engager to enter the clinic.” commented Dr Sonia Quaratino, Chief Medical Officer at Innate Pharma.
  • In this context, IPH6501 represents an innovative option for the treatment of patients with R/R B-cell non-Hodgkin’s lymphomas and has the potential to fulfil a large unmet need.”